PF‑08098488
/ Pfizer
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 11, 2026
PF‑08098488, A Novel CEACAM5-Targeting MMAE ADC with Optimized Engineered-Cysteine Sites Designed to Enhance Therapeutic Index, Demonstrates Potent Antitumor Activity in Preclinical Models
(EORTC-NCI-AACR 2026)
- "Abstract will be available as of 4 November (with consent of the author)"
ADC • Preclinical • Oncology • CEACAM5
1 to 1
Of
1
Go to page
1